John C. Reed
Insider Reports History
- Location
- New Brunswick, NJ
- Signature
- /s/ Joleen Morgan, as attorney-in-fact for John C. Reed
- All insider transactions
- Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date
Holdings reported by John C. Reed:
| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| JOHNSON & JOHNSON | EVP, Innovative Medicine, R&D | Employee Stock Options (Right to Buy) | 59,854 | $6,860,360 | $157.92 | 17 Feb 2026 | Direct |
| JOHNSON & JOHNSON | EVP, Innovative Medicine, R&D | Common Stock | 10,658 | $2,589,894 | $243.00 | 17 Feb 2026 | Direct |
| JOHNSON & JOHNSON | EVP, Innovative Medicine, R&D | Restricted Share Units | 3,546 | $864,915 | $156.15 | 15 Feb 2026 | Direct |
Insider Reports Filed by John C. Reed
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| JNJ | JOHNSON & JOHNSON | 15 Feb 2026 | 15 | -$5,224,221 | 4 | EVP, Innovative Medicine, R&D | 18 Feb 2026, 21:12 |
| JNJ | JOHNSON & JOHNSON | 17 Oct 2025 | 3 | -$4,185,793 | 4 | EVP, Innovative Medicine, R&D | 20 Oct 2025, 19:13 |
| JNJ | JOHNSON & JOHNSON | 17 Jul 2025 | 1 | -$3,129,830 | 4 | EVP, Innovative Medicine, R&D | 18 Jul 2025, 16:12 |
| JNJ | JOHNSON & JOHNSON | 01 May 2025 | 3 | -$1,719,723 | 4 | EVP, Innovative Medicine, R&D | 05 May 2025, 17:10 |
| JNJ | JOHNSON & JOHNSON | 15 Feb 2025 | 2 | $0 | 4 | EVP, Innovative Medicine, R&D | 19 Feb 2025, 17:29 |
| JNJ | JOHNSON & JOHNSON | 15 Feb 2025 | 3 | -$60,118 | 4 | EVP, Innovative Medicine, R&D | 18 Feb 2025, 21:11 |
| JNJ | JOHNSON & JOHNSON | 01 May 2024 | 3 | -$1,588,177 | 4/A | EVP, Innovative Medicine, R&D | 31 Oct 2024, 17:57 |
| JNJ | JOHNSON & JOHNSON | 15 Feb 2024 | 2 | $0 | 4 | EVP, Innovative Medicine, R&D | 20 Feb 2024, 17:55 |
| JNJ | JOHNSON & JOHNSON | 01 May 2023 | 1 | $0 | 4 | EVP, Pharmaceuticals R&D | 02 May 2023, 17:21 |
| JNJ | JOHNSON & JOHNSON | 03 Apr 2023 | 0 | $0 | 3 | EVP, Pharmaceuticals R&D | 13 Apr 2023, 17:10 |